Increased healthcare costs by later stage cancer diagnosis
Top Cited Papers
Open Access
- 13 September 2022
- journal article
- research article
- Published by Springer Nature in BMC Health Services Research
- Vol. 22 (1) , 1-12
Abstract
Background: Cancer represents a significant source of disease burden in the United States (US), both clinically and economically. Diagnosis and treatment of cancer at earlier stages may reduce this burden. To better understand potential impacts of earlier diagnosis, healthcare costs among patients with cancer were assessed by cancer type and stage at diagnosis.Methods: A retrospective analysis was conducted using Optum’s de-identified Integrated Claims-Clinical data set with Enriched Oncology, which includes data from Medicare Advantage and commercially insured members. Adult members newly diagnosed with solid tumor cancers, cancer stage at diagnosis (diagnosed 1/1/2016–6/30/2020), and continuous enrollment for at least one month post diagnosis were identified. Patients with breast, cervical, colorectal, lung, ovarian, or prostate cancer were reported. Mean standardized costs (2020 USD) were calculated in each month on an annual and cumulative basis through four years post-cancer diagnosis. In each month, costs were calculated for those with continuous enrollment and no death reported in the month. Mean annual cost per patient was estimated by summing month one to 12 mean costs and stratifying by stage at cancer diagnosis; annual year one to four costs were summed to determine cumulative costs.Results: Among members diagnosed 2016–2020 with breast, cervical, colorectal, lung, ovarian, or prostate cancer, 20,422 eligible members were identified. Mean costs increased by stage of diagnosis across all cancers at the annual and cumulative level through year four post diagnosis. Cumulative mean costs grew over time at a relatively similar rate across stages I to III and more dramatically in stage IV, except for cervical and lung cancer where the rate was relatively stable or slightly fluctuated across stages and ovarian cancer where stages III and IV both increased more sharply compared to stages I and II.Conclusions: Mean annual and cumulative healthcare costs through year four post cancer diagnosis were significantly higher among those diagnosed at later versus earlier cancer stages. The steeper increase in cumulative costs among those diagnosed in stage IV for many cancer types highlights the importance of earlier cancer diagnosis. Earlier cancer diagnosis may enable more efficient treatment, improve patient outcomes and reduce healthcare costs.Keywords
Funding Information
- GRAIL, LLC, a subsidiary of Illumina, Inc.
This publication has 19 references indexed in Scilit:
- Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic ArthritisAdvances in Therapy, 2020
- Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stageBMC Cancer, 2019
- Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal CancerThe Oncologist, 2019
- Health Care Expenditure Burden of Cancer Care in the United StatesINQUIRY: The Journal of Health Care Organization, Provision, and Financing, 2019
- Global treatment costs of breast cancer by stage: A systematic reviewPLOS ONE, 2018
- Medical Care Costs Associated With Cancer in Integrated Delivery SystemsJournal of the National Comprehensive Cancer Network, 2018
- Estimating Cost Savings from Early Cancer DiagnosisData, 2017
- Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service2016
- Economic Burden of Cancer in the United States: Estimates, Projections, and Future ResearchCancer Epidemiology, Biomarkers & Prevention, 2011
- Overview of Methods to Estimate the Medical Costs of CancerMedical Care, 2009